HO-1

Heme oxygenase-1 (HO-1, HMOX1) is an inducible stress-response enzyme that catalyzes the rate-limiting degradation of heme into biliverdin, carbon monoxide (CO), and ferrous iron, thereby contributing to cellular redox homeostasis and heme turnover^[1][2]. Mechanistically, HO-1 functions as a major cytoprotective pathway activated by oxidative stress, inflammation, hypoxia, ischemia-reperfusion injury, and other cellular stressors, where its enzymatic products participate in antioxidant, anti-inflammatory, anti-apoptotic, and immunomodulatory processes^[1][3][4]. Through regulation of oxidative and inflammatory signaling networks, HO-1 influences macrophage polarization, endothelial cell responses, and tissue protection in multiple experimental disease models, including vascular inflammation, acute lung injury, sepsis, hepatic ischemia-reperfusion injury, renal injury, and atherosclerosis^[3][4][2]. In disease contexts, increased HO-1 activity is generally associated with reduced inflammatory tissue damage and improved cellular adaptation to stress, supporting its broad relevance in studies of inflammation, cardiovascular disease, organ injury, and immune regulation^[3][4][2]. Compared with related isoforms, HO-1 is highly inducible, whereas HO-2 is constitutively expressed under homeostatic conditions; a third isoform, HO-3, has been reported but appears to have limited functional significance relative to HO-1 and HO-2^[2]. This inducible nature distinguishes HO-1 as the principal stress-responsive member of the heme oxygenase family and makes it a widely used experimental target for mechanistic studies^[2]. For experimental applications, pharmacological inducers such as hemin are commonly used to increase HO-1 expression, while competitive metalloporphyrin inhibitors including tin protoporphyrin (SnPPIX) and zinc protoporphyrin (ZnPPIX) are employed to investigate HO-1-dependent biological effects and validate pathway involvement in preclinical models^[4][2].